The article describes the insurance coverage and prices of weight loss drugs in the US, especially GLP-1 and GIP agonists. In 2025, commercial insurance companies became more stringent in providing coverage for these drugs, with the number of people without coverage for Zepbound increasing by more than 180%, meaning that more than 97 million people do not have coverage for these drugs. Even with Wegovy, which has extended coverage, up to 88% of insureds must meet additional conditions such as prior approval or step therapy. In all, about 19 million people with commercial insurance do not have coverage for any of these weight loss drugs. Medicare and Medicaid historically do not cover weight loss drugs, including GLP-1, and a planned coverage expansion in 2026 has been canceled, with coverage costs estimated by the Congressional Budget Office to be $35 billion over 2026–2034. However, some large firms began covering these drugs for their employees in 2025, with 43% of firms with more than 5,000 employees providing coverage. TRICARE covers weight loss drugs only under certain conditions, with stricter regulatory measures starting in August 2025. Medicare prices for drugs like Ozempic, Wegovy, Mounjaro and Zepbound have been reduced to $245, less than half of the original proposed price.